FDA全球物质注册数据库(FDA Global Substance Registration System)
物质名称LONCASTUXIMAB
异名/同义词IMMUNOGLOBULIN G1, ANTI-(HUMAN CD19 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL RB4V1.2 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL RB4V1.2 .KAPPA.-CHAIN, DIMER
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS B-LYMPHOCYTE ANTIGEN CD-19)CHIMERIC MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-449) (MUS MUSCULUS VH (IGHV1-69*02 (86%) (IGHD)-IGHJ4*01)) (8.8.13) (1-120) -HOMO SAPIENS IGHG1*03 (CH1(K97>R(217)), CH3(K107>DEL(450))), (121-449)) (223-211')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-211') (MUS MUSCULUS V-KAPPA (IGKV4-70*01 (91%) IGKJ1*01) (5.3.7) (1'-104') -HOMO SAPIENS IGKC*01 (105'-211')), DIMER (229-229'':232-232'')-BISDISULFIDE
LONCASTUXIMAB
LONCASTUXIMAB [INN]
LONCASTUXIMAB [USAN]
CAS登记号1875032-68-0
物质唯一标识(Unique Ingredient Identifier)NYM5HO7I39
分子式
国际化合物标识(International Chemical Identifier,InChI)
SMILES
分子结构式
欧洲化学品管理局注册号(ECHA)
成分类型 / INGREDIENT SUBSTANCE
关联数据
  • 药品国际非专利名称数据库
扩展资源
©2006-2026 Drugfuture->FDA Global Substance Registration System